No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial
| Autor: | Majid Malekmohammad, Payam Tabarsi, Lida Fadaeizadeh, Zahra Abtahian, Hamidreza Jamaati, Abdolbaset Vahedi, Abdolreza Mohamadnia, Alireza Dastan, Seyed Mohammadreza Hashemian, Esmaeil Mortaz, Fatemeh Yassari, Farzaneh Dastan, Afshin Moniri, Behrooz Farzanegan, Majid Marjani, Ali Saffaei, Fatemeh Monjazebi, Sara Haseli |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Adult Male ARDS medicine.drug_class medicine.medical_treatment SARS-Cov-2 Anti-Inflammatory Agents Article Dexamethasone law.invention 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Randomized controlled trial law medicine Corticosteroids Humans Treatment Failure Aged Pharmacology Mechanical ventilation Respiratory Distress Syndrome business.industry Mortality rate COVID-19 Length of Stay Middle Aged medicine.disease Respiration Artificial COVID-19 Drug Treatment 030104 developmental biology Anesthesia Etiology Corticosteroid Female business Tomography X-Ray Computed Negative Results 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | European Journal of Pharmacology |
| ISSN: | 1879-0712 0014-2999 |
| Popis: | The aim of this study was to evaluate the clinical effects of dexamethasone administration in patients with mild to moderate acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19). The study included 50 patients who were randomly assigned to the dexamethasone group or control group. Dexamethasone was administered at a dose of 20 mg/day from day 1-5 and then at 10 mg/day from day 6-10. The need for invasive mechanical ventilation, death rate, duration of clinical improvement, length of hospital stay, and radiological changes in the computed tomography scan were assessed. The results revealed that 92% and 96% of patients in the dexamethasone and control groups, respectively, required noninvasive ventilation (P = 0.500). Among them, 52% and 44% of patients in the dexamethasone and control groups, respectively, required invasive mechanical ventilation (P = 0.389). At the end of the study, 64% of patients in the dexamethasone group and 60% of patients in the control group died (P = 0.500); the remaining patients were discharged from the hospital during the 28-day follow-up period. The median length of hospital stay was 11 days in the dexamethasone group and 6 days in the control group (P = 0.036) and the median length of hospital stay was 7 days in the dexamethasone group and 3 days in the control group (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect